TY - JOUR
T1 - The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome
T2 - a randomized double-blind placebo-controlled clinical trial
AU - Salekzamani, Shabnam
AU - Bavil, Abolhassan Shakeri
AU - Mehralizadeh, Hossein
AU - Jafarabadi, Mohammad Asghari
AU - Ghezel, Aymaral
AU - Gargari, Bahram Pourghassem
N1 - Funding Information:
This study was funded by the Research Vice Chancellor, Tabriz University of Medical Sciences (Tabriz, Iran); Grant Number (5/71/1353). The results of this article are derived from the Ph.D. thesis of Shabnam Salekzamani (No. D/36) registered in the Tabriz University of Medical Sciences, Tabriz, Iran. The authors thank the staff of Nutrition Research center for their kindly cooperation in this study. The authors express gratitude to Dr. Navid Heydari for refining the manuscript language. The authors also appreciate all the patients for their participation in this research.
Publisher Copyright:
© 2017, Springer Science+Business Media New York.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Purpose: Metabolic syndrome may predispose to cardiovascular diseases. Since, in recent studies, vitamin D is advocated for cardioprotective roles, this study was designed to investigate the effects of vitamin D supplementation on proatherogenic inflammatory markers and common carotid intima media thickness in subjects with metabolic syndrome. Methods: This randomized double blind clinical trial was conducted in Tabriz, Iran. Eligible subjects (n = 80) with metabolic syndrome were recruited thorough advertisement and randomized to receive either vitamin D (50,000 IU/week) or matching placebo for 16 weeks. Interlukin-6, high sensitivity C-reactive protein, vascular cell adhesion molecule-1, E-selectin, and common carotid intima media thickness were measured at the beginning and end of the study. The study was registered at http://www.irct.ir (code: IRCT201409033140N14). Results: Sixteen weeks supplementation with vitamin D increased median of serum 25-hydroxy vitamin D [25(OH)D] and mean calcium levels (p < 0.001) in the intervention group. There was also a significant difference in parathyroid hormone level at the end of the study (p < 0.001). Vitamin D treatment reduced IL-6 level after 16 weeks (p = 0.027). Compared to baseline, vascular cell adhesion molecule-1 and E-selectin levels decreased significantly in vitamin D treated subjects; however, there were no significant differences between two groups. No effect of vitamin D supplementation was observed in either common carotid intima media thickness or high sensitivity C-reactive protein concentrations at the end of the study (p > 0.05). Conclusions: Vitamin D supplementation improved some proatherogenic inflammatory markers in subjects with metabolic syndrome. No changes of high sensitivity C-reactive protein and carotid intima media thickness were shown after 16 weeks.
AB - Purpose: Metabolic syndrome may predispose to cardiovascular diseases. Since, in recent studies, vitamin D is advocated for cardioprotective roles, this study was designed to investigate the effects of vitamin D supplementation on proatherogenic inflammatory markers and common carotid intima media thickness in subjects with metabolic syndrome. Methods: This randomized double blind clinical trial was conducted in Tabriz, Iran. Eligible subjects (n = 80) with metabolic syndrome were recruited thorough advertisement and randomized to receive either vitamin D (50,000 IU/week) or matching placebo for 16 weeks. Interlukin-6, high sensitivity C-reactive protein, vascular cell adhesion molecule-1, E-selectin, and common carotid intima media thickness were measured at the beginning and end of the study. The study was registered at http://www.irct.ir (code: IRCT201409033140N14). Results: Sixteen weeks supplementation with vitamin D increased median of serum 25-hydroxy vitamin D [25(OH)D] and mean calcium levels (p < 0.001) in the intervention group. There was also a significant difference in parathyroid hormone level at the end of the study (p < 0.001). Vitamin D treatment reduced IL-6 level after 16 weeks (p = 0.027). Compared to baseline, vascular cell adhesion molecule-1 and E-selectin levels decreased significantly in vitamin D treated subjects; however, there were no significant differences between two groups. No effect of vitamin D supplementation was observed in either common carotid intima media thickness or high sensitivity C-reactive protein concentrations at the end of the study (p > 0.05). Conclusions: Vitamin D supplementation improved some proatherogenic inflammatory markers in subjects with metabolic syndrome. No changes of high sensitivity C-reactive protein and carotid intima media thickness were shown after 16 weeks.
KW - Adhesion molecules
KW - Inflammation
KW - Metabolic syndrome
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=85019259548&partnerID=8YFLogxK
U2 - 10.1007/s12020-017-1317-2
DO - 10.1007/s12020-017-1317-2
M3 - Article
C2 - 28509078
AN - SCOPUS:85019259548
SN - 1355-008X
VL - 57
SP - 51
EP - 59
JO - Endocrine
JF - Endocrine
IS - 1
ER -
